The original research drug medical insurance renewal has not been completed, generic drugs on the top! Under the influence of the control fee, the original research substitution accelerated.

Medical Network August 7 - Hunan Provincial Health Insurance Bureau recently issued "on the Hunan Province Medical Insurance Special Drug Renewal (Signing) Contract Notice" (hereinafter referred to as "Notice"), 27 drug renewal (signing) contract successfully incorporated into the province's medical insurance special drug use management scope.
compared with the province's first two years of special drugs included in the scope, this time in the original research drug at the same time, including a number of domestic generic drugs, including a number of countries focused on the procurement of winning varieties.
noteworthy, according to the Notice, there are two original drug renewal signed unsuccessfully.
in addition, the four drugs directly transferred from the medical insurance catalogue and the scope of special drugs: acetate, lapatinib, fluorovirs, recombinant human interferon beta-1b, are the products of the national negotiations unsuccessfully and did not enter the new national drug catalog.
some analysts believe that the local special drugs to the national drug negotiations as anchor, the scope of tightening has been a major trend, under the influence of health insurance fees, the original research replacement will continue to accelerate.
renewal (signature) of the variety of domestic accounted for 80% according to the Hunan Provincial Health Insurance Bureau announced the news, this renewal (signature) about 27 drugs, involving non-small cell lung cancer, multiple myeloma, lymphoma, leukemia, prostate cancer and pulmonary arterial hypertension and other therapeutic areas.
12 renewals, with an average decline of 11.47 per cent and a maximum decrease of 32 per cent, while 15 new signings were added, with an average decrease of 20.56 per cent and a maximum decrease of 56.11 per cent.
industry comments that such a range is not unexpected, according to the notice issued by Hunan Province, enterprises should submit a special drug renewal application report including the clinical efficacy of drugs (including comparative analysis with competing products), drug approval since the market price changes across the country (including participation in national health insurance negotiations and tender procurement prices), as well as the whole of 2018, the whole of 2019 and the first quarter of 2020 in Hunan Province, the total number of hospitals and drugstores sold in the total number of patients and patients.
" from the Hunan Provincial Health Insurance Bureau requested to submit the materials and the final results can be seen that the local-oriented health care negotiations have gradually stepped on track.
" "Pharmaceutical Economics" reporter noted that the successful renewal (signing) of the contract of the gifitini, linadoamine, Ektini, methyl sulfonate Imadini, lithoscoid, boratizomi, Abitron, Dashatini, Anlistin, etc., are belonging to the original special drug species in Hunan Province, has entered the new version of the national "drug catalog" of the second part of the variety of production enterprises.
taking into account the patient's drug adjustment needs, Hunan this time to the unsuccessful renewal of the contract of Greve and Van Rick also set up a six-month and three-month transition period, clearly in the transition period, has been to enjoy the treatment of the drug to continue to pay for special drug medical insurance, new patients special medicine medical insurance will not be paid.
"Notice" also additional reminder, all places should do a good job in this renewal of the unsuccessful set up a transition period of drugs and direct transfer of drugs policy interpretation work, guide the agreement medical institutions and fixed-point pharmacies to do a good job of patient replacement drug protection.
commercial insurance feasible? From the Hunan Province this year's changes in the scope of special medicine is not difficult to see, the variety of national talks will become the anchor point of special medicine.
in March this year, Hunan will be 31 drugs into the province's special drug use management scope, the implementation of the state-mandated medical insurance payment standards and limit the scope of payment, the basis is to "do a good job in the state to negotiate the landing of drugs."
can be said that with the clarity of health care policy, relying on local additions to expand the market in urgent need of change.
in the eyes of market analysts, in the context of health insurance fees, commercial insurance should also be taken into account.
in fact, in some cities health insurance has liberalized the pilot allowed for commercial insurance supplements.
, for example, from 2017 in Shanghai, the health insurance department will, in the same way as the banking and insurance supervision departments and industries, pilot the medical insurance personal account to purchase commercial medical insurance products, and launch edited two proprietary products, "Inpatient out-of-pocket expenses compensation medical insurance" and "major illness insurance".
more typical is the recent rely on the advantages of the policy of the first zone hainan province.
earlier this month, led by Boao Lecheng International Medical Tourism Advance Zone, Hainan Provincial Government under the guidance of the launch of the first provincial-level customized Huimin-type global special drug insurance "Hainan Free Trade Port Boao Lecity Global Special Drug Insurance", covering 70 kinds of new anti-cancer drugs, of which 49 domestic unlisted new special drugs.
for overseas special drug use needs, patients need to make an appointment in lecheng first area of Hainan Boao Evergrande International Hospital and Hainan Boao Super Hospital to the hospital, before taking medication.
but there are also industry insiders to remind that, although in the second half of this year to deepen the key tasks of medical reform also mentioned "encourage commercial insurance institutions to provide medical, disease, rehabilitation, care, fertility and other comprehensive health insurance products and services, including medical, disease, rehabilitation, care, fertility and other comprehensive health insurance products and services", but objectively the current commercial health insurance has not played a corresponding role.
According to data released by the China Insurance Regulatory Commission, commercial health insurance premium income reached 706.6 billion yuan in 2019, nearly one-third of the income of the basic health insurance fund, but the compensation expenditure was only 235.1 billion yuan, accounting for 10% of the basic health insurance expenditure.
.